屏风生脉胶囊联合沙美特罗替卡松气雾剂治疗支气管哮喘的临床研究

目的探讨屏风生脉胶囊联合沙美特罗替卡松气雾剂治疗支气管哮喘的临床疗效。方法选取2015年9月—2016年9月在杭州师范大学附属医院进行治疗的支气管哮喘患者84例,根据治疗方案的差别分为对照组(42例)和治疗组(42例)。对照组吸入沙美特罗替卡松气雾剂,1吸/次,2次/d。治疗组在对照组的基础上口服屏风生脉胶囊,3粒/次,3次/d。两组患者均治疗4周。观察两组患者临床疗效,同时比较两组患者治疗前后临床症状消失的时间、第1秒用力呼气容积(FEV1)、用力肺活量(FVC)、最大呼气流速(PEF)等肺功能指标、血清学指标的变化。结果治疗后,对照组和治疗组总有效率分别为80.95%、95.24%,两组总有效率比较差异有统计学意义(P0.05)。两组患者喘憋、咳嗽、肺部啰音消失的时间较对照组均显著缩短,两组比较差异具有统计学意义(P0.05)。两组患者FEV1、FVC、PEF均较同组治疗前明显升高,同组治疗前后差异具有统计学意义(P0.05);且治疗组升高程度优于对照组,两组比较差异有统计学意义(P0.05)。两组患者血清IL-4、IL-6、TNF-α和NO水平明显低于同组治疗前,而IL-10、SOD水平明显高于同组治疗前(P0.05);且治疗组上述指标的改善程度更显著(P0.05)。结论屏风生脉胶囊联合沙美特罗替卡松气雾剂治疗支气管哮喘效果显著,可有效改善患者临床症状和肺功能,并可降低机体炎性反应,具有一定的临床推广应用价值。

Clinical study on Pingfeng Shengmai Capsules combined with Salmeterol Xinafoate and Fluticasone Propionate Aerosol in treatment of bronchial asthma

Objective To investigate the clinical efficacy of Pingfeng Shengmai Capsules combined with Salmeterol Xinafoate and Fluticasone Propionate Aerosol in treatment of bronchial asthma. Methods Patients (84 cases) with bronchial asthma in Hangzhou Normal University Affiliated Hospital from September 2015 to September 2016 were divided into control group (42 cases) and treatment group (42 cases) based on different treatments. Patients in the control group were inhalation administered with Salmeterol Xinafoate and Fluticasone Propionate Aerosol, 1 suck/time, twice daily. Patients in the treatment group were po administered with Pingfeng Shengmai Capsules on the basis of the control group, 3 grain/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and clinical symptoms disappeared time, pulmonary function indexes FEV1, FVC, and PEF and serological indexes in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 80.95%and 95.24%, respectively, and there were differences between two groups (P<0.05). After treatment, clinical symptoms disappeared time of wheezing, cough, and lung rale in two groups was decreased with significant difference between two groups (P<0.05). FEV1, FVC, and PEF levels in two groups were increased, and there were significant differences between two groups before and after treatment (P<0.05). And the increase degree of FEV1, FVC, and PEF levels in the treatment group was more significant than that in the control group (P<0.05). The levels of IL-4, IL-6, TNF-α, and NO in two groups were lower than those before treatment, while the levels of IL-10 and SOD were higher than those before treatment (P<0.05). And the improve degree of those indexes in the treatment group was more significant than that in the control group (P<0.05). Conclusion Pingfeng Shengmai Capsules combined with Salmeterol Xinafoate and Fluticasone Propionate Aerosol has a significant clinical effect in treatment of bronchial asthma, can improve clinical symptoms and pulmonary function, and decrease system inflammatory response, which has a certain clinical application value.